GlaxoSmithKline's Hasit Joshipura: Seeing a Healthy Future for India's Pharma Industry
Ask about Knowledge at Wharton
Episode Description
GlaxoSmithKline (GSK) was among the first foreign pharmaceutical companies to enter India decades ago and is viewed "almost like an Indian company," according to Hasit Joshipura, vice president-south Asia and managing director for GSK in India. During an interview with India Knowledge@Wharton at the recent Wharton India Economic Forum in Philadelphia, Joshipura suggested that GSK's years of experience in India may soon pay significant dividends as it prepares to create a "branded generics portfolio, apart from our own pipeline, in emerging markets." He also spoke about the future of pharmaceutical regulation in India, which he believes will align more closely with Western models in terms of monitoring drug development and new product launches. Read the transcript at: http://knowledge.wharton.upenn.edu/india/article.cfm?articleid=4373
Read the full transcriptHide the full transcript
- the 2009 wharton india economic forum titled india the road ahead took place in philadelphia and brought together
- CEOs of leading indian companies investors heads of nonprofit organizations sports celebrities and
- bollywood stars to discuss where india is headed in an age of economic uncertainty Indian knowledge at Wharton
- brings you one-on-one conversations with these leaders thanks for joining us today could you tell us how the
- pharmaceutical industry in India has changed since the early 90s when there was the wave of liberalisation for
- corporations in general there well thanks Steve thanks for having me here well first of all I don't think the
- liberalisation has a direct impact on the pharmaceutical industry however I think there has been an indirect impact
- in the sense that a liberal addition has brought in you know greater economic prosperity and that has in turn driven
- demand for quality health care and so I think that's driven the growth in pharmaceutical industry if you like the
- second piece indirectly dishonest liberalisation has also created an interest in India in general that
- focused the attention on the R&D capabilities in India and therefore has attracted the attention of the you know
- the global inorder companies and tell us about that R&D capability are we talking
- about the clinical study capability is it the research capability the the the scientific knowledge that's available
- well it's actually all because if you if you if you really see the genetic development the generic industry really
- demonstrated a very significant chemistry capability but that was not the first point of contact because the
- first point of contact came from the fact that the global pharma companies needed to reduce costs of bringing a
- molecule to market and the largest piece in that is clinical R&D you have a large
- patient pool in India and which is also you know treatment knife so I think the first place where companies went in was
- pinnacle R&D then having understood the infrastructure the capabilities the country different companies have taken
- different route some have gone to chemistry some have gone to early discovery so the different routes that
- people have taken so there seems to be a big difference between what a foreign company wants to do within India and
- what the domestic companies want to do in terms of exporting generics or building a global business outside of
- India could you talk about that difference please yes you see I think up until 2005 we had a patent law which was
- different from the rest of the world we had a process patent law now everybody knew that post 2005 we would have a
- patent law which was like most other countries in the world which is product patent now that that necessitated that
- the Indian companies look for avenues for growth beyond you know what they're being the model they've been following
- earlier and I think as a result of that a lot of them went out and and expanded the generic business globally and so
- that's that's been the route three generic companies have taken could you just explain how that has changed in the
- patent law would drive Indian companies to to look beyond borders well I think up until 2005 Indian companies could
- could replicate or reverse-engineer a product which was on patterned elsewhere in the world and they would get a
- process patent for it so so it was not a product pattern through the process patent post 2005 it's a product pattern
- now therefore Indian companies cannot use that as a as a basis for growth and therefore they needed to look for other
- growth drivers global expanding the the the generic footprint globally was one such opportunity which companies have
- taken now as far as you know where the companies are concerned it's the reverse that they suddenly now begin to see
- India as a very attractive opportunity apart from the fact that you know the traditional markets are not growing as
- fast and therefore there is a general focus on emerging markets in health care within that India because now it's it's
- compliant with the international patent law has become very attractive so companies which which are not playing in
- the Indian market global companies are now sort of there is a rush to come back so India offers certain
- low-cost advantages when it comes to performing clinical trials for example what about outsourcing other kinds of
- R&D actually creating new molecules and that that kind of activity yet that activity is also picked up fairly
- substantially as I was mentioning the discussion up under 2005 the the model for growth of Indian companies was quite
- different now there are different compartments so actually post 2005 in the last four years itself we've seen a
- very substantial increase in the number of patterns being filed globally by Indian companies the amount of work that
- they are they're doing to bring the first Indian molecule to market how does your company fit into this picture
- because your company Glaxo has been in India much longer than most foreign pharmaceutical companies yes so I would
- imagine you have different strategies that you're pursuing from somebody others yeah that's true now I think
- we're seen almost like an Indian company so that so that's that's that's a plus in the Indian market the success of the
- Indian model has actually you know led our new CEO to try and replicate that in a flash of markets which is now called
- the emerging markets which he thinks is going to drive growth for GSK globally and really what what they're trying to
- do is to build a branded generics portfolio apart from our own pipeline in emerging markets because that's the kind
- of model which works and that and and that the inspiration for that has come from the success of GSK in India because
- GSK in India developed a business model which was India specific many many years
- ago so they moved manufacturing to India they therefore they could they could price the product appropriately and
- which is why they've been able to develop such a substantial footprint in the country and that's the model now
- they're trying to replicate this way what about some other activities for India's pharma companies for example
- apart from drugs going off patent in generics and the things we've just discussed what about personalized
- genomics based medicine biotech is is alchemy genomics but biotech certainly is one which I think some companies have
- pursued big time and there was a belief that once the guidelines for follow-on biologics become
- get into place both in Europe in the US then that would be a big opportunity some companies gone that true
- genomic-based Mets in there are some initial beginnings by people who've come back from from other parts of the world
- and have started operations in India but my guess is biotech will will develop faster than genomics based medicine
- what about prevention of sickness yeah well first of all I think we like the generic pharmaceutical industry I think
- India also now is beginning to show signs of a fairly well-developed vaccine industry so there are a number of local
- vaccine companies are doing extremely well when I were able to you know provide product to UNICEF and the other
- Gavi and the others so certainly I think I think the vaccine side there's fair degree of activity
- prevention of sickness generally I think requires dissemination of good practices
- good hygiene and all of which is work which is being done either by government agencies under the National Rural Health
- Mission or by NGOs advocating safe practices so I think there is work in that area on as well and I think that's
- getting demonstrated in the continued decline in some of our you know mortality rates and improvement in our
- health care statistics what kind of changes do you see in the regulatory structure going forward yeah I need any
- further big loose innings yeah I think yeah sure I think India so far has had a you know almost like a dichotomy as far
- as regulating sexuals and so in a state level regulate instruction then you had a national regulator section what is
- being envisaged is an FDA type of structure which will then encompass not just drug approval but also
- pharmacovigilance also you know monitoring of trials or all activities surrounded or associated with drug
- development and and launch of new products so I think in the next couple of years we are going to see that kind
- of a structure come into play and I think then we will have a regulatory system which is comparable to the best
- in the world India has had a lot of small manufacturers which will be facing some difficulties in meeting the new
- scrutiny that's that's going on in manufacturing in India do you have any plans to work with some
- of those small companies to help bring them along collaborate what what is your level of collaboration with any
- companies at this point yeah well about 45 50 percent of our current product portfolio is outsourced to contact
- manufacturers so we're already working with you know fairly large numbers of not small but medium sized players whose
- manufacturing practices we've upgraded to meet with our standards of quality so I think we've been doing it not just now
- we've been doing for many years one of the key things that ending companies need to do to move to the next level of
- serving worldwide markets two or three key things well I think they're already serving worldwide markets I really don't
- think it's more in terms of doing key things I think it's more in the sense of now focusing on the right side of
- building area is focusing on the right opportunity so that they find these these you know international forests
- profitable enough to be sustainable there's big changes coming in the u.s. in healthcare we don't know what they
- are but we all know that they're coming how will that affect the export of say generics from India what are the
- opportunities there well I think the changes would largely be be governed by two things if I read the tea leaves one
- is that a the cost of healthcare is prohibitive in the US if it's very expensive so you know I want to maybe
- bring it down and secondly if you want to make it available to those who don't have access today and if those be the
- the considerations then I have no doubts that Indian genetic players will have a
- significant opportunity because of the cost of manufacture and the quality at which the cost of quality combinations
- that they're able to deliver does that mean you would be more interested in in perhaps taking over some smaller
- companies so that you increase your manufacturing base to be able to deliver more to the US no I think we being a
- global company we have our own subsidy in the u.s. serving the US market so I don't think I don't think that that is
- the intent or will be the intent but there is a stated intent of going into branded generics in the emerging markets
- and to the N and if that requires that we go and acquire you somebody who can do it for us then yes
- but other words not not as a source for manufacturing GSK products and sending them elsewhere no that's not the intent
- okay so in addition to changes in US healthcare system the other big thing that you're probably working with is the
- worldwide economic downturn now health care tends to be resistant to down translate they tend to not be as
- affected as much but can you speak to how your company is being affected in India and elsewhere by the worldwide
- downturn no I can talk about India so far in India not just our company the market we haven't seen any impact
- lastly the market were ten percent which is which is you know which is in line with what is expected I you know given
- the level of penetration of healthcare in India I I don't think that we may not see an acceleration of this growth rate
- but I would be surprised if the growth sort of drops below this are there specific disease categories or other
- categories where you see big opportunities opening up whether there's going to be more insurance money
- available or whether there's just a bush to to solve the problems with particular
- diseases it's well known that you know Indians are particularly susceptible to cardiovascular diseases and diabetes so
- these two are slated to become you know the biggest healthcare problem for India
- and then associate of diabetes you've got the other problems of end organ failure and lot of that so I think in
- that whole area we're going to some challenges and this is something it's not an opportunity but I think it's it's
- something which the government is working on and we need to work on to make sure that there's enough awareness
- about about Indians being susceptible to this and doing something about it and India has long been known as having an
- advantage when it comes to low cost and now everyone's concerned about the high cost of health care particularly in the
- US but it's it's becoming a big concern worldwide how can you leverage India's reputation as a low-cost producer to
- increase market share well first of all you know when you say India's low-cost is
- to the West I mean if you if you look at cost of health care in India in relation
- to India has been going up fairly substantially so so that's not good news for Indians but having said that I think
- the fact that there is economic growth the fact that the insurance is opening up health insurance opening up is
- resulting in a substantial increase in demand for quality health care so you're seeing a number of tertiary care
- hospitals over last year coming up now all of these can also provide services to - you know the itinerant medical care
- seeker so medical tourism is expected to grow fairly substantially over the next
- several years and I hope that the capacity build also happens concurrently so that that just doesn't mean that
- there's a cost arbitrage but the cost of health care for Indians goes up
Brief Summary
India's pharmaceutical industry evolves post-liberalization, focusing on generics and R&D while facing global economic challenges.
Key points
- The 2009 Wharton India Economic Forum. A gathering of CEOs, investors, and celebrities to discuss India's economic future.
- Changes in India's Pharmaceutical Industry. The pharmaceutical industry has evolved significantly since the early 90s due to liberalization.
- Emerging Opportunities in Healthcare. India's healthcare market is seeing growth in personalized medicine and vaccine production.





